(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.
The cell-based therapeutics company said new patents cover its neural stem cell-derived exosomes and their methods of production. The patents were secured in China, Japan, Korea and Europe.
ReNeuron said it is targeting its exosome technology programme towards business partnerships in which its exosomes may be exploited as a novel vector for delivering third-party biological drugs.
Following these patent grants, ReNeuron's patent estate consists of over 40 patents worldwide, covering its cell-based therapies and exosome technology.
"We are pleased to have received these recent patent grants relating to our exosome technology platform. We expect to build this patent estate further in the near future," said Chief Executive Olav Hellebo.
ReNeuron shares were trading 0.2% lower on Tuesday in London at 237.00 pence each.
Reneuron (RENE)